The University of Chicago Header Logo

Connection

Tao Xie to Humans

Back to Details
This is a "connection" page, showing publications Tao Xie has written about Humans.
Tao Xie
Connection Strength
0.655
Humans
  1. Healthcare access and utilization of deep brain stimulation and supplementary care in black and white patients with Parkinson's disease. Parkinsonism Relat Disord. 2025 Nov; 140:108057.
    View in: PubMed
    Score: 0.030
  2. Multiple System Atrophy. Continuum (Minneap Minn). 2025 Aug; 31(4):1000-1022.
    View in: PubMed
    Score: 0.030
  3. Bedside Assessment of Downgaze Limit by Amplitude. Mov Disord Clin Pract. 2025 Dec; 12(12):2224-2231.
    View in: PubMed
    Score: 0.030
  4. Effect of dopaminergic medications on Montreal Cognitive Assessment in Parkinson's disease patients. Parkinsonism Relat Disord. 2025 Sep; 138:107951.
    View in: PubMed
    Score: 0.030
  5. Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease". Mov Disord. 2024 Apr; 39(4):760-761.
    View in: PubMed
    Score: 0.027
  6. Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome. Mov Disord. 2023 02; 38(2):304-312.
    View in: PubMed
    Score: 0.025
  7. Disparities in diagnosis, treatment and survival between Black and White Parkinson patients. Parkinsonism Relat Disord. 2021 06; 87:7-12.
    View in: PubMed
    Score: 0.022
  8. Disease course and treatment patterns in progressive supranuclear palsy: A real-world study. J Neurol Sci. 2021 Feb 15; 421:117293.
    View in: PubMed
    Score: 0.022
  9. Interference of subcutaneous implantable cardioverter defibrillator by deep brain stimulation. Parkinsonism Relat Disord. 2020 12; 81:75-77.
    View in: PubMed
    Score: 0.021
  10. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018 09; 89(9):989-994.
    View in: PubMed
    Score: 0.018
  11. Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease. Mov Disord. 2017 01; 32(1):176.
    View in: PubMed
    Score: 0.016
  12. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
    View in: PubMed
    Score: 0.016
  13. Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy. Mov Disord. 2025 Nov; 40(11):2517-2530.
    View in: PubMed
    Score: 0.015
  14. Author Response. Neurology. 2015 Aug 11; 85(6):557.
    View in: PubMed
    Score: 0.015
  15. Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS. Neurology. 2015 Aug 04; 85(5):479-80.
    View in: PubMed
    Score: 0.015
  16. Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology. 2015 Jan 27; 84(4):415-20.
    View in: PubMed
    Score: 0.014
  17. Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials. Mov Disord. 2024 Aug; 39(8):1329-1342.
    View in: PubMed
    Score: 0.014
  18. GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians. Mov Disord. 2024 Apr; 39(4):728-733.
    View in: PubMed
    Score: 0.014
  19. DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology. 2014 Feb 18; 82(7):636-7.
    View in: PubMed
    Score: 0.013
  20. Multi-ancestry genome-wide association meta-analysis of Parkinson's disease. Nat Genet. 2024 Jan; 56(1):27-36.
    View in: PubMed
    Score: 0.013
  21. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012 Oct 16; 79(16):1744; author reply 1744.
    View in: PubMed
    Score: 0.012
  22. Diagnostic biomarkers of Parkinson's disease: what gain at what cost? J Neurol Neurosurg Psychiatry. 2012 Aug; 83(8):769.
    View in: PubMed
    Score: 0.012
  23. Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012 Oct; 83(10):1015-7.
    View in: PubMed
    Score: 0.012
  24. Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. Mov Disord. 2012 May; 27(6):799-800.
    View in: PubMed
    Score: 0.012
  25. Using global team science to identify genetic parkinson's disease worldwide. Ann Neurol. 2019 08; 86(2):153-157.
    View in: PubMed
    Score: 0.010
  26. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 03; 60:138-145.
    View in: PubMed
    Score: 0.009
  27. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
    View in: PubMed
    Score: 0.009
  28. Dystonia treatment: Patterns of medication use in an international cohort. Neurology. 2017 Feb 07; 88(6):543-550.
    View in: PubMed
    Score: 0.008
  29. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025.
    View in: PubMed
    Score: 0.008
  30. Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome. Alzheimers Dement. 2025 Jul; 21(7):e70485.
    View in: PubMed
    Score: 0.007
  31. Automated Imaging Differentiation for Parkinsonism. JAMA Neurol. 2025 May 01; 82(5):495-505.
    View in: PubMed
    Score: 0.007
  32. Survey of common deep brain stimulation programming practices by experts in Parkinson's Disease. J Neurol. 2024 Dec 12; 272(1):49.
    View in: PubMed
    Score: 0.007
  33. The Black and African American Connections to Parkinson's Disease (BLAAC PD) study protocol. BMC Neurol. 2024 Oct 21; 24(1):403.
    View in: PubMed
    Score: 0.007
  34. Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B). Ann Neurol. 2024 Dec; 96(6):1092-1103.
    View in: PubMed
    Score: 0.007
  35. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
    View in: PubMed
    Score: 0.007
  36. Common Variants Near ZIC1 and ZIC4 in Autopsy-Confirmed Multiple System Atrophy. Mov Disord. 2022 10; 37(10):2110-2121.
    View in: PubMed
    Score: 0.006
  37. Recommendations for Virtual Administration of the PSP Rating Scale. Mov Disord. 2022 09; 37(9):1960-1961.
    View in: PubMed
    Score: 0.006
  38. A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Mov Disord. 2022 06; 37(6):1265-1271.
    View in: PubMed
    Score: 0.006
  39. Pan-cancer analyses reveal genomics and clinical characteristics of the melatonergic regulators in cancer. J Pineal Res. 2021 Oct; 71(3):e12758.
    View in: PubMed
    Score: 0.006
  40. Melatonin reverses nasopharyngeal carcinoma cisplatin chemoresistance by inhibiting the Wnt/ß-catenin signaling pathway. Aging (Albany NY). 2020 03 23; 12(6):5423-5438.
    View in: PubMed
    Score: 0.005
  41. N-Oxide polymer-cupric ion nanogels potentiate disulfiram for cancer therapy. Biomater Sci. 2020 Mar 17; 8(6):1726-1733.
    View in: PubMed
    Score: 0.005
  42. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy. Biomaterials. 2020 05; 240:119902.
    View in: PubMed
    Score: 0.005
  43. Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling. Cell Rep. 2020 02 11; 30(6):1935-1950.e8.
    View in: PubMed
    Score: 0.005
  44. Consensus Paper: Experimental Neurostimulation of the Cerebellum. Cerebellum. 2019 Dec; 18(6):1064-1097.
    View in: PubMed
    Score: 0.005
  45. Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.005
  46. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.005
  47. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp. 2019 12 01; 40(17):5094-5107.
    View in: PubMed
    Score: 0.005
  48. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol. 1999 Jul; 56(1):31-8.
    View in: PubMed
    Score: 0.005
  49. Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord. 2019 08; 65:178-183.
    View in: PubMed
    Score: 0.005
  50. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558.
    View in: PubMed
    Score: 0.005
  51. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Lancet. 1998 Jun 27; 351(9120):1966.
    View in: PubMed
    Score: 0.005
  52. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018 02; 33(2):282-288.
    View in: PubMed
    Score: 0.004
  53. High resolution single strand conformation polymorphism analysis using formamide and ethidium bromide staining. Mol Pathol. 1997 Oct; 50(5):276-8.
    View in: PubMed
    Score: 0.004
  54. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord. 1997 May; 12(3):426-7.
    View in: PubMed
    Score: 0.004
  55. Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord. 2016 12; 31(12):1874-1882.
    View in: PubMed
    Score: 0.004
  56. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord. 2016 06; 31(6):924-32.
    View in: PubMed
    Score: 0.004
  57. Pathological findings of anti-Yo cerebellar degeneration with Holmes tremor. J Neurol Neurosurg Psychiatry. 2015 Jan; 86(1):121-2.
    View in: PubMed
    Score: 0.003
  58. Anticholinergic responsive cyclic myoclonus. Mov Disord. 2013 Mar; 28(3):401-2.
    View in: PubMed
    Score: 0.003
  59. Distribution of catechol-O-methyltransferase expression in human central nervous system. Neuroreport. 1998 Aug 24; 9(12):2861-4.
    View in: PubMed
    Score: 0.002
  60. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology. 2003 Dec; 45(7):1011-8.
    View in: PubMed
    Score: 0.002
  61. Further studies in xenobiotic metabolism and Parkinson's disease. Adv Neurol. 2001; 86:105-13.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.